Application of antibacterial peptide in preparation of propionibacterium acnes resisting medicine
通过使用多肽GKY25作为抗菌肽,针对现有痤疮治疗药物的耐药性和不良反应问题,开发了一种新型抗痤疮药物,显著抑制痤疮丙酸杆菌,解决了现有药物的耐药性和不良 Response problems provide more effective therapeutic effects.
Patent Information
- Application Number
- CN202411200824.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
Existing acne treatment drugs such as antibiotics and isotretinoin can easily lead to drug resistance and adverse reactions after long-term use, and the treatment effect will decrease, and new anti-acne drugs are lacking.
Using the known polypeptide GKY25 as an antibacterial peptide, it has significant inhibitory and antibacterial effects on Propionibacter acnes, and is used to prepare antiacne drugs, including its amino acid sequence, fusion protein and polypeptides with similar functions but amino acid sequence variants, binding to nucleic acid molecules and Recombinant microorganisms form pharmaceutical compositions for topical administration.
A new anti-acne drug candidate molecule is provided, which significantly inhibits Propionibacter acnes, reduces the inflammatory response, and is effective against drug-resistant strains, reducing the risk of adverse drug reactions.
Smart Images

Figure CN119055753A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to application of an antimicrobial peptide in the preparation of an anti-Propionibacterium acnes drug. Background Art
[0002] Acne is a common skin problem, especially in adolescents and young people. It not only affects the patient's appearance, but may also cause psychological problems, such as inferiority, anxiety and depression. Therefore, the study of effective acne treatment methods can significantly improve the patient's quality of life and enhance self-confidence and social skills. Propionibacterium acnes is a lipophilic, anaerobic bacterium. Its large-scale reproduction in hair follicles is one of the key factors in the onset of acne. When the hair follicle opening is blocked and the oil increases, Propionibacterium acnes will multiply rapidly and decompose the triglycerides in the sebum to produce free fatty acids. These free fatty acids are highly irritating and can stimulate inflammatory reactions in the hair follicle wall and surrounding tissues, leading to the formation of acne. Commonly used therapeutic drugs in the market include antibiotics, isotretinoin, etc. Clindamycin can quickly relieve acne symptoms, but it is easy to relapse after discontinuation of the drug, and long-term use is easy to produce drug resistance, resulting in decreased efficacy; isotretinoin has a good therapeutic effect in mild and severe acne, and long-term use will also cause a series of adverse reactions, such as dryness and inflammation of the skin and mucous membranes, liver and kidney burden, skeletal muscle effects, neuropsychiatric changes and reproductive system effects. Therefore, it is necessary to develop a new class of anti-acne drugs.
[0003] The peptide GKY25 (Kasetty, Gopinath, et al.) was identified in human wounds as a C-terminal host defense peptide of thrombin. The peptide exhibits antimicrobial activity against Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa, Gram-positive bacteria Staphylococcus aureus, and fungi Candida albicans. The peptide causes local perturbations and disruptions in the cell membranes of Pseudomonas aeruginosa and Staphylococcus aureus, and reduces the expression of inflammatory factors in mouse models, which may involve binding and neutralization with LPS, resulting in subsequent inhibition of toll-like receptor signaling, or including interactions with CD14, TLRs, or intracellular receptors, to achieve the effect of reducing inflammation.
[0004] The applicant unexpectedly discovered in the process of screening candidate polypeptides with anti-Propionibacterium acnes properties in a polypeptide database that the known polypeptide GKY25 has significant inhibitory and antibacterial effects on Propionibacterium acnes that causes acne, and can be used as a novel candidate drug for anti-acne drugs. Summary of the invention
[0005] The purpose of the present invention is to provide an application of an antimicrobial peptide in the preparation of an anti-Propionibacterium acnes drug in view of the above-mentioned deficiencies of the prior art. The antimicrobial peptide is a known polypeptide GKY25, which has a strong bactericidal ability against Propionibacterium acnes, expanding the new use of the polypeptide GKY25.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] The first object of the present invention is to provide an application of an antimicrobial peptide in the preparation of an anti-Propionibacterium acnes drug, wherein the antimicrobial peptide is specifically the following A1) or A2) or A3):
[0008] A1) The amino acid sequence is shown in SEQ ID NO.1;
[0009] A2) a fusion protein obtained by connecting a tag to the N-terminus or / and the C-terminus of A1);
[0010] A3) is a polypeptide having 90% or more identity with SEQ ID NO.1 and having the same function as A1, obtained by substituting and / or deleting and / or adding some amino acid residues to the amino acid sequence of SEQ ID NO.1.
[0011] In order to facilitate the purification of the polypeptide in A1), the tags shown in the following table can be connected to the amino terminus or carboxyl terminus of the polypeptide consisting of the amino acid sequence shown in SEQ ID No. 1 in the sequence listing: Poly-Arg (RRRRR), Poly-His (HHHHHH), FLAG (DYKDDDK).
[0012] Furthermore, the Propionibacterium acnes includes Propionibacterium acnes vulgaris and drug-resistant Propionibacterium acnes, the Propionibacterium acnes vulgaris is ATCC 11827, and the drug-resistant Propionibacterium acnes is a strain resistant to clindamycin or erythromycin.
[0013] Furthermore, the minimum inhibitory concentration of the antimicrobial peptide against ATCC 11827 is 16 μg / mL.
[0014] Furthermore, the minimum inhibitory concentration of the antimicrobial peptide against the drug-resistant Propionibacterium acnes is 128 μg / mL.
[0015] Furthermore, the antimicrobial peptide can inhibit the activity of Propionibacterium acnes biofilm and the production of lipase.
[0016] The second object of the present invention is to provide the use of the above-mentioned antimicrobial peptide-related biomaterial in the preparation of an anti-Propionibacterium acnes drug, wherein the biomaterial is any one of the following B1) to B6):
[0017] B1) a nucleic acid molecule encoding the antimicrobial peptide according to claim 1;
[0018] B2) an expression cassette containing the nucleic acid molecule described in B1);
[0019] B3) a recombinant vector containing the nucleic acid molecule described in B1);
[0020] B4) a recombinant microorganism containing the nucleic acid molecule described in B1);
[0021] B5) a recombinant microorganism containing the expression cassette described in B2);
[0022] B6) A recombinant microorganism containing the recombinant vector described in B3).
[0023] Furthermore, the nucleic acid molecule is as follows 1) or 2):
[0024] 1) The coding sequence is the DNA molecule of SEQ ID No. 2 in the sequence list;
[0025] 2) The DNA molecule shown as SEQ ID No. 2 in the sequence listing.
[0026] Furthermore, the Propionibacterium acnes includes Propionibacterium acnes vulgaris and drug-resistant Propionibacterium acnes, the Propionibacterium acnes vulgaris is ATCC 11827, and the drug-resistant Propionibacterium acnes is a strain resistant to clindamycin or erythromycin.
[0027] The third object of the present invention is to provide a pharmaceutical composition comprising an antimicrobial peptide having an amino acid sequence as shown in SEQ ID NO.1 or a pharmaceutically acceptable salt thereof for use in the preparation of an anti-Propionibacterium acnes drug.
[0028] Furthermore, the antimicrobial peptide is the only effective active ingredient.
[0029] The pharmaceutical composition of the present invention is preferably administered topically, particularly for the treatment of skin, and may be in the form of an ointment, cream, emulsion, balm, powder, gel, spray, lotion or suspension. It may also be in the form of a controlled release microsphere or nanosphere or a suspension of lipid or polymer vesicles, or a polymer patch and hydrogel. Such topical compositions may be in anhydrous form, aqueous form or emulsion form.
[0030] The pharmaceutical composition may be a hydrogel containing ingredients of hypromellose and propylene glycol.
[0031] The term "identity" used in the present invention refers to the identity of an amino acid sequence or a nucleotide sequence. The identity of an amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST page on the NCBI homepage website. For example, in Advanced BLAST 2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting the Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively, and searching for the identity of a pair of amino acid sequences for calculation, the value of identity (%) can then be obtained.
[0032] The term "polypeptide with the same function" used in the present invention is the same or similar to the meaning conventionally understood by those skilled in the art, and refers to that the amino acid sequence of a certain fragment is a part of the amino acid sequence of a complete protein or polypeptide, and has the same or similar function or activity as the complete protein or polypeptide. It should be understood by those of ordinary skill in the art that changing a few amino acid residues in certain regions of a polypeptide, such as non-important regions, will not substantially change the biological activity. For example, the sequence obtained by appropriately replacing certain amino acids will not affect its activity (see Watson et al., Molecular Biology of The Gene, Fourth Edition, 1987, The Benjamin / Cummings Pub. Co. P224). Therefore, those of ordinary skill in the art are able to implement such replacements and ensure that the resulting molecules still have the desired biological activity.
[0033] The term "Propionibacterium acnes vulgaris" as used in the present invention means that Propionibacterium acnes is associated with acne vulgaris.
[0034] The term "drug-resistant Propionibacterium acnes" used in the present invention means that Propionibacterium acnes is resistant to certain antibiotics. The drug resistance in the present invention is erythromycin resistance and clindamycin resistance.
[0035] Compared with the prior art, the present invention has the following beneficial effects:
[0036] The present invention provides an application of an antimicrobial peptide in the preparation of an anti-Propionibacterium acnes drug. The antimicrobial peptide is a known polypeptide GKY25, which has significant inhibitory and antibacterial effects on Propionibacterium acnes that causes acne, and provides a new lead candidate molecule for the clinical treatment of acne. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 Mass spectrometry identification of peptide GKY25
[0038] Figure 2 Tissue sections showing the effect of peptide GKY25 on acne model rats
[0039] Figure 3 Effect of polypeptide GKY25 on biofilm formation of Propionibacterium acnes
[0040] Figure 4 This is the effect of polypeptide GKY25 on the secretion of Propionibacterium acnes lipase. DETAILED DESCRIPTION
[0041] In order to make the purpose, technical solution and advantages of the present invention clearer, embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements with the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and cannot be understood as limiting the present invention.
[0042] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods, usually according to conventional conditions such as the conditions described in the "Molecular Cloning Experiment Guide (4th Edition)" (Chinese version) published by Science Press, or according to the conditions recommended by the manufacturer. They are experimental operations well known to those skilled in the art and the present invention is not limited thereto.
[0043] Example 1
[0044] Preparation of polypeptide GKY25.
[0045] Step S1, synthesizing the nucleotide sequence of the gene encoding GKY25
[0046] The GKY25 gene was synthesized by chemical methods and provided by Nanjing GenScript Biotech Co., Ltd. The nucleotide sequence encoding GKY25 is shown in SEQ ID NO.2, and the amino acid sequence of GKY25 is shown in SEQ ID NO:1;
[0047] Step S2, cloning the coding gene of GKY25 obtained in step S1 into a plasmid vector yeast expression vector to obtain recombinant plasmids pPIC9-GKY25, pPIC9k-GKY25, and pPICZa-GKY25.
[0048] The expressed target gene sequence was optimized according to the yeast codon usage preference.
[0049] The coding gene of GKY25 and the plasmid vector pPIC9k were double-digested with EcoRI and NotI to recover the target fragment, and the gene fragment of GKY25 and the pPIC9k vector fragment were ligated with T4 ligase to obtain a recombinant plasmid, which was sequenced by DNA sequencing;
[0050] Step S3, introducing the recombinant plasmid pPIC9k-GKY25 obtained in step S2 into the host bacteria
[0051] The pPIC9k-GKY25 expression plasmid successfully constructed in step S2 was linearized, recovered by ethanol precipitation, and then electroporated into the competent cells of yeast GS115 strain (purchased from Beijing Qingke Biotechnology Co., Ltd.) at 1500V, 25nf, and 1200Ω. After electroporation, 1ml of pre-cooled 1M sorbitol was added to the electroporation cup and ice bathed for two minutes. In the clean bench, the contents of the electroporation cup were gently transferred to a sterile EP tube, placed in a 30°C shaker, and cultured at 250rmp for 1-2h to restore the vitality of the yeast cells after clicking. Further centrifuge at room temperature for 5min, discard 500μL of supernatant and resuspend, draw the bacterial solution and apply it to the MD medium plate, and culture at 30°C for about 3 days until white yeast colonies grow. Add 2 ml of sterilized water to the surface of the MD plate, gently blow off the bacteria with a pipette, and spread them on a YPD plate containing 0.5 mg, 2 mg, or 4 mg of geneticin resistance, and invert and culture at 30°C for about 3 days. Pick a single colony from the plate and culture it in 10 mL of YPD medium to obtain genetically engineered bacteria;
[0052] Step S4, inoculate the positive monoclonal bacterial solution of the host bacteria obtained in step S3 into 25 ml of BMGY medium, and culture at 250 rpm and 30°C until the OD 600nm >10.0. Centrifuge at 8000g for 10 min and discard the supernatant. Resuspend the bacteria in BMMY medium and dilute the bacterial solution to an OD of about 1.0. Add 1% anhydrous methanol and then add 1% anhydrous methanol every 24 hours for induction. Cultivate at 250rpm and 30℃ for 48 hours. After induction, centrifuge and discard the bacteria to obtain the supernatant containing GKY25 polypeptide.
[0053] Step S5, extract and purify the supernatant of the soluble GKY25 polypeptide obtained in step S4. Add 40% ammonium sulfate to the supernatant to obtain a GKY25 polypeptide precipitate, dissolve the precipitate with PBS, perform chromatography purification and separation, collect the target solution, and freeze-dry to obtain the target GKY25.
[0054] The results are as follows Figure 1 Shown is the mass spectrometry identification diagram of GKY25, and the molecular weight of the freeze-dried product is correct.
[0055] SEQ ID NO.2:
[0056] GGTAAGTACGGATTCTACACTCACGTTTCAGACTGAAGAAGTGGATCAAAGTCATTGATTTCGGTGAA
[0057] SEQ ID NO.1:
[0058] GKYGFYTHVFRLKKWIOKVIDOFGE.
[0059] Example 2
[0060] Evaluation of the antibacterial activity of peptide GKY25 against Propionibacterium acnes.
[0061] Preparation of bacterial suspension
[0062] Take the test strain, inoculate it on the reinforced Brucella blood agar medium, and culture it anaerobically at 37℃ for 46 to 50 hours.
[0063] Preparation of bacterial suspension: Transfer the bacteria to 2 mL of brain heart infusion broth and culture for 6-24 hours or until sufficient turbidity is obtained. Use physiological saline to adjust the turbidity to 0.5 McFarland standard, and then dilute the bacterial suspension to 10 with brain heart infusion broth. 6 CFU / mL.
[0064] Table 1. Strain information table.
[0065]
[0066] The different Propionibacterium acnes shown in Table 1 are all pathogens that can cause acne.
[0067] Drug dissolution and dilution
[0068] GKY25 and clindamycin were accurately weighed, and sterilized with sterile water to a concentration of 1024 μg / mL as a stock solution, which was then filtered for sterilization. Gradient dilutions were performed with broth medium to obtain a series of drug solutions with concentrations of 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.12, and 0.06 μg / mL.
[0069] Inoculation and cultivation
[0070] Pipette 100 μL of the above-mentioned different concentrations of drug solution into a sterile 96-well plate, and add 100 μL of bacterial suspension to each well. Set up a positive control well: 100 μL bacterial solution + 100 μL culture medium; negative control well: 200 μL culture medium. Incubate at 37°C in an anaerobic environment for 46-50 hours, take out the results, and record the growth status.
[0071] The results showed that the MIC of GKY25 against ATCC 11827 was 16 μg / mL, and the MIC against the resistant strain CC(R) was 128 μg / mL. The MIC of clindamycin against ATCC 11827 was 8 μg / mL, and the MIC against CC(R) was 256 μg / mL. The MIC of GKY25 against clinically collected Propionibacterium acnes was 32 μg / mL. The MIC of clindamycin against clinically collected strains was 16 μg / mL. The MIC results are shown in Table 2.
[0072] Table 2. MIC results (μg / mL)
[0073]
[0074] Example 3
[0075] Efficacy experiment on rat acne model.
[0076] The experiment set up a normal control group (G1), a model control group (G2), a clindamycin hydrochloride gel group (G3), a low-dose GKY25 group (G4), a medium-dose GKY25 group (G5), and a high-dose GKY25 group (G6). After the experiment, the right auricle tissue was fixed with formalin and made into paraffin sections, and then stained with HE for histopathological examination and pathological scoring.
[0077] Oleic acid was applied once a day to the opening of the catheter on the inner side of the right ear of the rats, and Propionibacterium acnes was injected into the skin of the right ear of the rats every other day before application. Three weeks after modeling, 60 animals were randomly divided into a model control group (G2), a clindamycin hydrochloride gel group (G3), a low-dose GKY25 group (G4), a medium-dose GKY25 group (G5) and a high-dose GKY25 group (G6) according to the thickness of the auricle, with 6 animals in each group, half male and half female. Group G1 was the normal control group. Groups G1-G6 were given drugs through the ear, and the model control group was given an equal amount of GKY25 blank gel twice a day, with an interval of at least 4 hours between two administrations, for 7 consecutive days. After the last administration, the animals were euthanized by inhalation of CO2 anesthesia and bleeding from the posterior abdominal aorta. The right auricle was fixed and made into paraffin sections, and histopathological examination was performed after HE staining.
[0078] The information of animal grouping in this experiment is shown in Table 3.
[0079] Table 3. Animal grouping information.
[0080]
[0081] The results are as follows Figure 2As shown in the figure, compared with the model control group (G2), the right auricle tissue of the animals in the low, medium and high dose groups (G4-G6) of GKY25 had a reduced degree of local tissue edema / granulation tissue formation and inflammatory cell infiltration. The degree of thickening of the epidermis layer of the right auricle tissue of the animals in the medium dose group (G5) and high dose group (G6) of GKY25 was significantly reduced. The above results show that 20μg / animal GKY25 has a certain therapeutic trend, and 40μg / animal and 60μg / animal GKY25 have a therapeutic effect.
[0082] Example 4
[0083] The effect of peptide GKY25 on Propionibacterium acnes biofilm was investigated.
[0084] Construction of Propionibacterium acnes biofilm. The in vitro construction method of the biofilm was based on the biofilm construction method of Capoor et al. The 96-well plate biofilm was constructed for XTT cell viability assay. The construction process was as follows: the pre-prepared concentration of 1x10 8 200 μl of CFUs / ml BHI medium bacterial suspension was pipetted into it. Cultured at 37°C in an anaerobic culture device. During this period, fresh BHI liquid culture medium was replaced every one to two days. Incubation continued, and the biofilm was measured at different preset time points. After biofilm preparation, GKY25 with mass concentrations of 16, 32, and 160 μg / mL was added for co-culture.
[0085] Activity determination by tetramethylrhodamine (XTT) method. It is used to determine the metabolic activity of the living part of the biofilm, so as to evaluate the activity of the biofilm and the growth of the biofilm. The general steps are as follows: Take out the 96-well plate containing the biofilm, first discard the supernatant, and use 1×PBS to wash the surface of the biofilm 3 times. Then add 100μL of XTT (0.5mg / mL) / Vit.K3 (10mM) mixed solution to each well. Wrap with aluminum foil to avoid light, and culture at 37℃ in an anaerobic culture device for 3h. Then absorb 50μL of supernatant from the above wells into the microplate reader plate and use a 490nm wavelength light source to determine the spectrophotometric value. The results showed that as the concentration of GKY25 increased, the activity of the biofilm became worse.
[0086] Example 5
[0087] The effect of peptide GKY25 on bacterial lipase release was investigated.
[0088] Propionibacterium acnes (1×10 9CFU / mL) was co-cultured with GKY25-Tween 80 solution at mass concentrations of 4, 16, and 160 μg / mL, and the control group was the same as before. After culturing for 8 hours under anaerobic conditions at 37°C and 180 r / min, the supernatant was centrifuged and the lipase content was detected using a lipase assay kit. The results showed that compared with the control group, the lipase in the culture medium with GKY25 added decreased with the increase in the drug concentration, and the secretion amount decreased by 67.2% and 80.6%, respectively.
[0089] For matters not mentioned above, the prior art applies.
[0090] Although some specific embodiments of the present invention have been described in detail through examples, those skilled in the art should understand that the above examples are for illustration only and are not intended to limit the scope of the present invention. Those skilled in the art to which the present invention belongs may make various modifications or supplements to the specific embodiments described or replace them in a similar manner, but they will not deviate from the direction of the present invention or exceed the scope defined by the attached claims. Those skilled in the art should understand that any modifications, equivalent substitutions, improvements, etc. made to the above embodiments based on the technical essence of the present invention should be included in the protection scope of the present invention.
Claims
1. Application of an antimicrobial peptide in the preparation of an anti-Propionibacterium acnes drug, It is characterized in that The antimicrobial peptide is specifically the following A1) or A2) or A3): A1) The amino acid sequence is shown in SEQ ID NO.1; A2) a fusion protein obtained by connecting a tag to the N-terminus or / and the C-terminus of A1); A3) is a polypeptide having 90% or more identity with SEQ ID NO.1 and having the same function as A1, obtained by substituting and / or deleting and / or adding some amino acid residues to the amino acid sequence of SEQ ID NO.
1.
2. The use according to claim 1, It is characterized in that The Propionibacterium acnes includes Propionibacterium acnes vulgaris and drug-resistant Propionibacterium acnes. The Propionibacterium acnes vulgaris is ATCC 11827, and the drug-resistant Propionibacterium acnes is a strain resistant to clindamycin or erythromycin.
3. The use according to claim 2, It is characterized in that The minimum inhibitory concentration of the antimicrobial peptide to ATCC 11827 is 16 μg / mL.
4. The use according to claim 2, It is characterized in that The minimum inhibitory concentration of the antimicrobial peptide to the drug-resistant Propionibacterium acnes is 128 μg / mL.
5. The use according to claim 2, It is characterized in that The antimicrobial peptide can inhibit the activity of the Propionibacterium acnes biofilm and the production of lipase.
6. Use of the biomaterial related to the antimicrobial peptide according to claim 1 in the preparation of anti-Propionibacterium acnes drugs, It is characterized in that The biological material is any one of the following B1) to B6): B1) a nucleic acid molecule encoding the antimicrobial peptide according to claim 1; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1); B4) a recombinant microorganism containing the nucleic acid molecule described in B1); B5) a recombinant microorganism containing the expression cassette described in B2); B6) A recombinant microorganism containing the recombinant vector described in B3).
7. The use according to claim 6, It is characterized in that The nucleic acid molecule is as follows 1) or 2): 1) The coding sequence is the DNA molecule of SEQ ID No. 2 in the sequence list; 2) The DNA molecule shown as SEQ ID No. 2 in the sequence listing.
8. The use according to claim 7, It is characterized in that The Propionibacterium acnes includes Propionibacterium acnes vulgaris and drug-resistant Propionibacterium acnes. The Propionibacterium acnes vulgaris is ATCC 11827, and the drug-resistant Propionibacterium acnes is a strain resistant to clindamycin or erythromycin.
9. Use of a pharmaceutical composition comprising an antimicrobial peptide having an amino acid sequence as shown in SEQ ID NO. 1 or a pharmaceutically acceptable salt thereof in the preparation of an anti-Propionibacterium acnes drug.
10. The use according to claim 9, It is characterized in that The antimicrobial peptide is the only effective active ingredient.
